A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... February 16, 2021 Surveillance and Early Cancer Detection are Associated with Improved Survival in... September 1, 2021 New breast and lung cancer treatments approved in Scotland January 19, 2022 Colorectal Cancer Screening: The Silver Lining September 1, 2020 Load more HOT NEWS Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients... Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults “The power of science”: HPV vaccine proven to dramatically reduce cervical... Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991
